|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar
|
|
3
|
Ashktorab H and Brim H: DNA methylation
and colorectal cancer. Curr Colorectal Cancer Rep. 10:425–430.
2014. View Article : Google Scholar
|
|
4
|
Evers BM: Neurotensin and growth of normal
and neoplastic tissues. Peptides. 27:2424–2433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kalafatakis K and Triantafyllou K:
Contribution of neurotensin in the immune and neuroendocrine
modulation of normal and abnormal enteric function. Regul Pept.
170:7–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li J, Song J, Zaytseva YY, Liu Y, Rychahou
P, Jiang K, Starr ME, Kim JT, Harris JW, Yiannikouris FB, et al: An
obligatory role for neurotensin in high-fat-diet-induced obesity.
Nature. 533:411–415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mustain WC, Rychahou PG and Evers BM: The
role of neurotensin in physiologic and pathologic processes. Curr
Opin Endocrinol Diabetes Obes. 18:75–82. 2011. View Article : Google Scholar
|
|
8
|
Wu Z, Martinez-Fong D, Trédaniel J and
Forgez P: Neurotensin and its high affinity receptor 1 as a
potential pharmacological target in cancer therapy. Front
Endocrinol (Lausanne). 3:1842013.
|
|
9
|
Dupouy S, Mourra N, Doan VK, Gompel A,
Alifano M and Forgez P: The potential use of the neurotensin high
affinity receptor 1 as a biomarker for cancer progression and as a
component of personalized medicine in selective cancers. Biochimie.
93:1369–1378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Friess H, Zhu Z, Graber H,
Zimmermann A, Korc M, Reubi JC and Büchler MW: Neurotensin
receptor-1 mRNA analysis in normal pancreas and pancreatic disease.
Clin Cancer Res. 6:566–571. 2000.PubMed/NCBI
|
|
11
|
Souazé F, Dupouy S, Viardot-Foucault V,
Bruyneel E, Attoub S, Gespach C, Gompel A and Forgez P: Expression
of neurotensin and NT1 receptor in human breast cancer: A potential
role in tumor progression. Cancer Res. 66:6243–6249. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gui X, Guzman G, Dobner PR and Kadkol SS:
Increased neurotensin receptor-1 expression during progression of
colonic adenocarcinoma. Peptides. 29:1609–1615. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dupouy S, Viardot-Foucault V, Alifano M,
Souazé F, Plu-Bureau G, Chaouat M, Lavaur A, Hugol D, Gespach C,
Gompel A, et al: The neurotensin receptor-1 pathway contributes to
human ductal breast cancer progression. PLoS One. 4:e42232009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alifano M, Souazé F, Dupouy S,
Camilleri-Broët S, Younes M, Ahmed-Zaïd SM, Takahashi T,
Cancellieri A, Damiani S, Boaron M, et al: Neurotensin receptor 1
determines the outcome of non-small cell lung cancer. Clin Cancer
Res. 16:4401–4410. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Valerie NC, Casarez EV, Dasilva JO,
Dunlap-Brown ME, Parsons SJ, Amorino GP and Dziegielewski J:
Inhibition of neurotensin receptor 1 selectively sensitizes
prostate cancer to ionizing radiation. Cancer Res. 71:6817–6826.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JT, Li J, Song J, Lee EY, Weiss HL,
Townsend CM Jr and Evers BM: Differential expression and
tumorigenic function of neurotensin receptor 1 in neuroendocrine
tumor cells. Oncotarget. 6:26960–26970. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim JT, Li J, Jang ER, Gulhati P, Rychahou
PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, et al:
Deregulation of Wnt/β-catenin signaling through genetic or
epigenetic alterations in human neuroendocrine tumors.
Carcinogenesis. 34:953–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JT, Liu C, Zaytseva YY, Weiss HL,
Townsend CM Jr and Evers BM: Neurotensin, a novel target of
Wnt/β-catenin pathway, promotes growth of neuroendocrine tumor
cells. Int J Cancer. 136:1475–1481. 2015. View Article : Google Scholar
|
|
19
|
Evers BM, Ishizuka J, Chung DH, Townsend
CM Jr and Thompson JC: Neurotensin expression and release in human
colon cancers. Ann Surg. 216:423–430; discussion 430–431. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao D, Kuhnt-Moore S, Zeng H, Wu JS,
Moyer MP and Pothoulakis C: Neurotensin stimulates IL-8 expression
in human colonic epithelial cells through Rho GTPase-mediated
NF-kappa B pathways. Am J Physiol Cell Physiol. 284:C1397–C1404.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ning Y, Manegold PC, Hong YK, Zhang W,
Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, et al:
Interleukin-8 is associated with proliferation, migration,
angiogenesis and chemosensitivity in vitro and in vivo in colon
cancer cell line models. Int J Cancer. 128:2038–2049. 2011.
View Article : Google Scholar :
|
|
22
|
Kerkhoff E and Rapp UR: Cell cycle targets
of Ras/Raf signalling. Oncogene. 17:1457–1462. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Servotte S, Camby I, Debeir O, Deroanne C,
Lambert CA, Lapière CM, Kiss R, Nusgens B and Decaestecker C: The
in vitro influences of neurotensin on the motility characteristics
of human U373 glioblastoma cells. Neuropathol Appl Neurobiol.
32:575–584. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shimizu S, Tsukada J, Sugimoto T, Kikkawa
N, Sasaki K, Chazono H, Hanazawa T, Okamoto Y and Seki N:
Identification of a novel therapeutic target for head and neck
squamous cell carcinomas: A role for the neurotensin-neurotensin
receptor 1 oncogenic signaling pathway. Int J Cancer.
123:1816–1823. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Souazé F, Viardot-Foucault V, Roullet N,
Toy-Miou-Leong M, Gompel A, Bruyneel E, Comperat E, Faux MC, Mareel
M, Rostène W, et al: Neurotensin receptor 1 gene activation by the
Tcf/beta-catenin pathway is an early event in human colonic
adenomas. Carcinogenesis. 27:708–716. 2006. View Article : Google Scholar
|
|
26
|
Dong Z, Wang X, Zhao Q, Townsend CM Jr and
Evers BM: DNA méthylation contributes to expression of the human
neurotensin/neuromedin N gene. Am J Physiol. 274:G535–G543.
1998.PubMed/NCBI
|
|
27
|
Dong Z, Wang X and Evers BM: Site-specific
DNA méthylation contributes to neurotensin/neuromedin N expression
in colon cancers. Am J Physiol Gastrointest Liver Physiol.
279:G1139–G1147. 2000.PubMed/NCBI
|
|
28
|
Hagihara A, Miyamoto K, Furuta J, Hiraoka
N, Wakazono K, Seki S, Fukushima S, Tsao MS, Sugimura T and
Ushijima T: Identification of 27 5′ CPG islands aberrantly
methylated and 13 genes silenced in human pancreatic cancers.
Oncogene. 23:8705–8710. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan AC, Jimeno A, Lin SH, Wheelhouse J,
Chan F, Solomon A, Rajeshkumar V, Rubio-Viqueira B and Hidalgo M:
Characterizing DNA méthylation patterns in pancreatic cancer
genome. Mol Oncol. 3:425–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo S, Yan F, Xu J, Bao Y, Zhu J, Wang X,
Wu J, Li Y, Pu W, Liu Y, et al: Identification and validation of
the methylation biomarkers of non-small cell lung cancer (NSCLC).
Clin Epigenetics. 7:32015. View Article : Google Scholar : PubMed/NCBI
|
